Company / R&D per Share
GYRE THERAPEUTICS, INC. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.16
FY2025
5-year range
$0.16 / $3.12
FY2021-FY2025
Trend
+1.1%
vs FY2024
Sector context
#196 of 208
Health Care
What the data says
Among 208 Health Care companies, GYRE THERAPEUTICS, INC. is in the bottom 6% for r&d per share. R&D per Share has fluctuated over the past 10 years, ranging from $0.16 in FY2024 to $14.83 in FY2016.
Based on SEC 10-K filings.
0.16 in FY2025 with a 5-year CAGR of -46.6%.
Declined from $0.26 to $0.16 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -10.4%
- 5-Year CAGR
- -46.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 208This company $0.16 Sector average $12.19
▼
-98.7% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 1.1% year-over-year.
- Ranks #196 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2016.
- Lowest r&d per share in the period was in FY2024.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.16 | +1.1% |
| FY2024 | $0.16 | -40.2% |
| FY2023 | $0.26 | +19.0% |
| FY2022 | $0.22 | -92.9% |
| FY2021 | $3.12 | -14.4% |
| FY2020 | $3.64 | -0.7% |
| FY2019 | $3.67 | +73.7% |
| FY2018 | $2.11 | -43.7% |
| FY2017 | $3.75 | -74.7% |
| FY2016 | $14.83 | -26.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026